Tags : trastuzumab-pkrb

Biosimilars Biotech

Celltrion and Teva’s Herzuma (trastuzumab-pkrb, Herceptin biosimilar) Receives FDA’s Approval

Shots: The approval is based on non-inferiority data assessing Herzuma vs Herceptin (trastuzumab), testing its safety, efficacy, PK &PD, and immunogenicity The study demonstrated with bio-similarity in terms of purity, potency and safety between Herzuma and Herceptin in patients with HER2-overexpressing breast cancer Herceptin biosimilar, Herzuma (trastuzumab-pkrb) is a HER2/neu receptor antagonist, approved by the […]Read More